COMMUNIQUÉS West-GlobeNewswire

WeightWatchers Announces Strategic Leadership Team Appointments
10/09/2024
Additions of Chief Commercial Officer and Chief Impact Officer emphasize the Company’s continued focus on growth ahead of 2025 NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers [...]
Tersa Earth Partners with Wet’suwet’en First Nation to Advance Sustainable Economic Growth
10/09/2024
BURNS LAKE, British Columbia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Tersa Earth Innovations Inc. is excited to announce a strategic partnership with Yinka Dene Economic Development Limited Partnership (YLP), the economic [...]
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
09/09/2024
If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA follows FDA approval on August 9, 2024, of neffy (2 mg) [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/09/2024
BEDFORD, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024, Anika granted [...]
Relay Therapeutics Announces Proposed Public Offering of Common Stock
09/09/2024
CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
09/09/2024
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for the treatment of [...]
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
09/09/2024
September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline LAWRENCEVILLE, N.J., Sept. 09 [...]
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
09/09/2024
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- [...]
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
09/09/2024
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic [...]
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
09/09/2024
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
09/09/2024
DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable [...]
Terns Announces Proposed Public Offering
09/09/2024
FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Abivax presents first-half 2024 financial results
09/09/2024
Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX [...]
TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer
09/09/2024
SAN MATEO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- TriArm Therapeutics (“TriArm” or the “Company”), a clinical-stage, next-generation cell therapy company leveraging its global presence and core non-viral platform to [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
09/09/2024
TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the [...]
Recovery First Treatment Center Launches Evening Virtual Treatment Program in English and Spanish, Expanding Access to Care
09/09/2024
HOLLYWOOD, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- As the nation recognizes National Recovery Month, Recovery First Treatment Center has launched a virtual evening Intensive Outpatient Program (IOP) to help more people [...]
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
09/09/2024
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not [...]
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
09/09/2024
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR) 1 Preliminary activity in patients with [...]
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
09/09/2024
Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted [...]

Pages